Rafael vs XTL Biopharmaceuticals
RFL and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RFL and XTLB compare
Rafael scores higher on the StockData Score (5 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RFL | XTLB |
|---|---|---|
| Size and price | ||
| Market cap | $55.8M | – |
| Share price | $1.07 | $1.60 |
| Change, 1 year | −15.7% | −58.8% |
| Change, 5 years | −82.4% | −87.9% |
| Beta (5Y) | 0.84 | 0.98 |
| Employees | 17 | 3 |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 63.9× | – |
| P/B | 0.8× | – |
| FCF yield | −53.7% | – |
| Growth | ||
| Revenue growth (TTM) | −4.7% | – |
| Revenue growth, 5Y average | 1.7% | – |
| Profitability | ||
| Operating margin | −3823% | – |
| Net margin | −3391% | – |
| FCF margin | −3431% | – |
| Return on equity | −36.9% | – |
| Return on invested capital | −61.5% | – |
| Financial health | ||
| Interest coverage | −100.3× | −6.3× (better) |
| Current ratio | 2.35 | – |
| Altman Z-score | −2.49 | – |
| Piotroski F-score | 1 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 7.5% | 0.00% |
| Held by insiders | 39.2% | 0.00% |
| Short interest, % of float | 0.92% | – |
Go deeper
- RFL stock overview
- RFL income statement
- RFL valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.